Orlando Health Ventures

Orlando Health Ventures

Orlando Health Ventures is the strategic investment vehicle of Orlando Health, the private not-for-profit system founded in 1918 and anchored by Orlando Regional Medical Center, Arnold Palmer Hospital for Children, and Winnie Palmer Hospital for Women & Babies. The venture unit deploys the health system's balance sheet — Altss estimates the parent's investable asset pool above $2.5 billion — to back companies whose products can be piloted and proven across Orlando Health's own network of more than a dozen facilities in Central Florida. Unlike financial VCs, the team measures return in clinical adoption as much as IRR. Strategy spans seed through growth equity with a primary focus on healthcare delivery, digital health, and medical devices. The firm writes direct checks and co-invests alongside venture partners that include Rex Health Ventures, Solas BioVentures, and Arboretum Ventures — the last of which was a co-investor in Francis Medical, a urology-focused device company. Geographic deployment concentrates on US-based startups, though the parent system's footprint is entirely Florida. The investment structure favors equity rounds where Orlando Health can serve as a clinical reference site or first-adopting provider. The venture team recently added Principal Yuriy Onyskiv alongside Managing Director Bobby Helmedag, signaling a build-out from what was historically a single-leader effort. The parent organization operates additional commercial real estate LLCs and the Orlando Health Foundation, a philanthropic arm that raises separate charitable capital. Recent activity includes the continued expansion of co-investor relationships and an active pace of medtech and health-tech deals, though the firm has not publicly disclosed a deployment total. Orlando Health Ventures differs structurally from an endowment-style VC program: it reports through the operating health system, not a separate foundation board, which means investment theses are tested daily inside ICUs, surgical suites, and outpatient clinics. That tight operating-company tether gives portfolio companies a commercialization path that pure-play financial VCs cannot replicate on their own.